Pregnant people diagnosed with late latent or latent of unknown duration syphilis are recommended to receive three intramuscular doses of benzathine penicillin G, with each dose administered no more than 9 days apart. Evidence on whether shorter intervals within that 9‑day window affect risk of congenital syphilis has been limited. The analysis described here evaluates outcomes by dosing interval in a multijurisdictional U.S. dataset covering 2018–2023.
Data were collected from eight U.S. jurisdictions between 2018 and 2023. The work was led by investigators from the Centers for Disease Control and Prevention together with staff from multiple state and local health departments. The analysis focused on pregnant women with late latent or latent of unknown duration syphilis who were treated with the three-dose benzathine penicillin G regimen and for whom dosing interval information was available.
The study compared outcomes for two interval groupings within the recommended treatment window: a 9‑day dosing interval and a 6–8‑day dosing interval between injections of benzathine penicillin G. The comparator groups reflect clinically relevant variations in scheduling that can occur in real-world prenatal care and public health programs.
The primary observation reported is that there was no significant difference in the risk of congenital syphilis between pregnancies in which maternal benzathine penicillin G doses were spaced at 9 days and those with doses spaced at 6–8 days. This result indicates that, within the evaluated window of up to 9 days between doses, shortening intervals to 6–8 days did not materially change the measured risk of congenital infection in this multijurisdictional cohort.
The report presents this finding succinctly as an absence of a statistically significant difference in congenital syphilis risk when comparing the 9‑day and 6–8‑day interval groups. No additional numerical results, subgroup analyses, or effect estimates are reported in the source summary beyond this comparative conclusion.
This activity was reviewed by CDC and conducted consistent with applicable federal law and policy; it was deemed public health surveillance and exempt from Institutional Review Board review. The investigators confirmed adherence to relevant ethical guidelines and reporting standards, and authors declared no competing interests.
The underlying data are collected under provisions of the Public Health Service Act and are protected by an Assurance of Confidentiality at CDC (Section 308(d) of the Public Health Service Act). Requests for access to the data are handled on a case by case basis and should be directed to the CDC contact provided in the report. The study was supported as regular CDC work and through cooperative agreements and contractual mechanisms; specific cooperative agreement identifiers and supporting divisions were reported by the authors.
Within the limitations of the summary presented, the finding that risk of congenital syphilis did not differ significantly between 9‑day and 6–8‑day penicillin dosing intervals suggests flexibility in scheduling within the recommended 9‑day window may not adversely affect congenital syphilis outcomes. These results are relevant for clinicians and public health programs that manage antenatal treatment for late latent or latent of unknown duration syphilis and may inform operational decisions when timely dosing is constrained.
Practitioners and programs should interpret these findings in the context of the full dataset and methods; the source summary does not provide detailed numeric results, confidence intervals, or stratified analyses. For operational or policy changes, stakeholders should consult the full preprint or contact the study authors or CDC for complete methods and data details.
This summary is based on a medRxiv preprint reporting analyses from eight U.S. jurisdictions for 2018–2023. The article lists CDC and state/local health department authors and indicates the preprint was posted on medRxiv. The authors reported no competing interests and noted adherence to applicable ethical and reporting guidelines. Requests for access to data are subject to CDC confidentiality protections and should be directed to the contact provided in the original report.